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INTRODUCTION
As previously reported, we have isolated a new
monomeric trypsin-like enzyme with a molecular
weight of 27kDa frommucoid sputum samples from
patients with chronic airway diseases, and have ar-
bitrarily named this enzyme human airway trypsin-like
protease (abbreviated as HAT for convenience) (1).
Recently, Yamaoka et al. have cloned the cDNA for
HAT, and have deduced the amino acid sequence
of HAT from the nucleotide sequence of its cDNA
(2). Their results indicated that HAT has a precursor
with a molecular weight of 47 kDa, and that HAT
isolated from the mucoid sputum corresponds to
its mature form. Moreover, Northen blot analysis
showed that the content of the messenger RNA for
HAT in the trachea was the largest among 12 hu-
man tissues analyzed (2). From these results, it was
considered that after the HAT precursor is synthe-
sized in the airway walls, and is changed into its
active and mature form (HAT) by limited proteolysis,
HAT is secreted or released into the mucous mem-
brane of the airway where it plays some physio-
logical roles such as cleaving of exogenous proteins
or endogenous proteins secreted or released into the
mucous membrane.
In a preliminary experiment, we examined the
hydrolyzing activities of mature HAT against major
human serum proteins, and found that among various
proteins, fibrinogen is the most prominently cleaved
by HAT.
In this study, we measured the content of fibrino-
gen in sputum samples from patients with chronic
airway diseases, and analyzed biochemically the
fibrinogenolytic activity of HAT, to clarify whether
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HAT can prevent fibrin deposition on the airway mu-
cous membrane by cleaving fibrinogen.
MATERIALS AND METHODS
Collection of sputum and purification of HAT
Mucoid and mucopurulent sputum samples were
collected from patients with chronic bronchitis
(CB) or bronchial asthma (BA) in a plastic container
kept in an ice bath, and stored at -20℃ until use. HAT
(approximately 7)waspurified aspreviously reported
(1) from about 900 of the pooled sputum sam-
ples. The purified material showed a single band on
SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
To measure fibrinogen in sputum, mucoid sputum
samples were collected from 22 patients with chronic
bronchitis (CB) and 26 patients with bronchial asth-
ma (BA), and purulent sputum samples were col-
lected from 27 patients with bronchiectasis. The
diagnoses of CB and BA were based on the criteria
of the Medical Research Council of the American
Thoracic Society (3). The BA group consisted of pa-
tients with BA of a moderate degree.
Materials
Fibrinogen and thrombin, which were purified from
human plasma, and bovine serum albumin (BSA),
were purchased from Sigma (St. Louis, MO). Fi-
brinogen was further purified by affinity chroma-
tography using lysine-Sepharose accord-ing to the
method of Masuda et al . (4), after purification ac-
cording to the method of Laki (5) with some modi-
fications. All the fluorogenic synthetic substrates
which had methylcoumarinamide (MCA) at their
COOH-termini, were purchased from the Peptide
Institute (Osaka, Japan). SephadexG-200was purchased
from Pharmacia Fine Chemicals (Uppsala, Sweden).
Human mast cell tryptase was purified as described
by Smith et al . (6) with minor modifications.
Methods of biochemical analysis
1) Assay of activities of HAT and elastase
Activities of these serine proteases were mea-
sured by spectrofluorometry using fluorogenic
MCA-substrates, which were synthesized by previ-
ous investigators for assaying each protease. HAT
(trypsin-like) and elastase-like activities were measured
by spectrofluorometry using Boc-Phe-Ser-Arg-MCA
(7) and Suc-Ala-Pro-Ala-MCA (8) as substrates, respec-
tively (1, 9). For assaying each protease, an assay
mixture (1.5) containing 50 mU Tris-HCl-pH 8.6,
100μM the synthetic MCA-substrate, 100/
BSA, and 50-200 μ of the test sample, was incubated
at 37℃ for 10-60 min, and then the reaction was
stopped by addition of 1 of 30% acetic acid. The
mixture was centrifuged at 2,500×g for 5 min,
and the fluorescence intensity of the released
aminomethylcoumarin (AMC) was measured. One
unit of activity was defined as the amount that gen-
erated 1 μmole of AMC per min.
2) Gel filtration of HAT, mast cell tryptase and mucoid
sputum extract through Sephadex G-200
The mucoid sputum samples from patients with
CB or BA were mixed with 9 volumes of 0.05 M
Tris-HCl buffer (pH8.6)-0.15 NaCl, homogenized
with a Polytron homogenizer (Kinematica, PT/35,
Littau, Switzerland) in an ice-bath for 30 sec, and
then centrifuged at 10,000×g for 10 min. Two of
the supernatant was applied to a column (2.2×65
cm) of Sephadex G-200 equilibrated with the same
buffer. Elution was carried out at a flow rate of 15
/hr at 4℃and the eluate was collected in fractions
of 4. About 80 mU of purified HAT or mast cell
tryptase was subjected to gel filtration in the same
way as described above, as control. Protease activity
was measured using 50-200 μ of the eluate.
3) Analysis of HAT-induced cleavage of fibrinogen
by SDS-PAGE
HAT-induced cleavage of fibrinogen was analyzed
by SDS-PAGE, using HAT at concentrations of
0.62-10 mU/ and fibrinogen at concentrations of
2,000/ and 4-16/.
Cleavage of 2,000/ fibrinogen by HAT :
The reaction mixture containing 2,000/
fibrinogen, different concentrations of purified
HAT (0.62-10 mU/),and 50 mU Tris-HCl (pH 8.6
or 7.4) in a total volume of 500 μ, was incubated
at 37℃ for10min-16hrs, and then promptly cooled
in an ice-bath. Ten μ of each of the mixtures was
subjected to SDS-PAGE on a 4-20% gradient gel
containing 0.1%SDS (Daiichi Pure Chemicals, Tokyo)
under a denaturing and reducing condition by the
method of Laemmli (10). The gels were stained with
coomassie brilliant blue. The gels were calibrated
with high range standards (Promega, Madison, WI).
Cleavage of 4-16/ fibrinogen by HAT :
The reaction mixture contained HAT and Tris-HCl
buffer at the same concentrations described above,
but fibrinogen at concentration of 4-16/ in a total
volume of 5. It was incubated at 37℃ for 4hrs,
concentrated using a vaporized centrifuge (CVE-100D,
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Tokyo Rika Kikai, Tokyo) to 0.5-1, and then dialyzed
against 1of saline. Twenty μof each sample was
subjected to SDS-PAGE under a denaturing and reduc-
ing condition as described above. SDS-PAGE low
range standards (APRO Science, Naruto-City, Japan),
were used as molecular weight markers. The gels
were silver-stained using a kit obtained from Daiichi
Pure Chemicals.
4) Analysis of HAT-induced cleavage of fibrinogen
by measuring released fibrinopeptide A (FPA)
Reaction mixtures which contained 2,000/
fibrino-gen, 5mU/ HAT, and 50mU Tris-HCl
(pH 7.4-9.4) or Hepes (pH 6.8-7.6) in a total volume
of 0.2, were incubated at 37℃ for 4hrs. Then released
FPA (or FPA-reactive peptide) was measured using
Asserachrom (Diagnostica Stago, Stago, France),
an EIA kit for FPA, according to the method of
Amiral et al (11).
5) Assay of clotting capacity of HAT-treated fibrinogen
The reaction mixtures containing 2000/ fibrino-
gen, 0.3-10 mU/ HAT, and 50 mU Tris-HCl (pH 7.4)
in a total volume of 0.25, were incubated at 37℃
for 10 min-16 hrs, and then cooled in an ice-bath to
stop the reaction. The HAT-treated fibrinogen solution
and a solution containing 2.5 unit/ thrombin in
50 mU Tris-HCl buffer (pH 7.4) were kept at room
temperature separately. Then the thrombin-induced
clotting time of the HAT-treated fibrinogen was
measured by incubating a mixture of 100 μeach
of HAT-treated fibrinogen and thrombin solution in
a plastic tube at 37℃. Clotting time was measured
in triplicate and the mean value was recorded. When
samples did not show formation of fibrin clot within
2 min, it was considered that fibrinogen had completely
lost its clotting capacity.
6) Measurement of albumin and fibrinogen concentrations
Albumin and fibrinogen in the sputum samples were
measured by sandwich enzyme-linked immunosorbent
assay (ELISA) (12). The albumin concentration was
measured according to the method of Tatenuma et
al. (13).
For ELISA of fibrinogen, we used sheep IgG
antibody against human fibrinogen (The Binding
Site, Birmingham, England) as the first antibody,
and goat IgG antibody against human fibrinogen
(Organon Teknika N.V. Cappel Products Aurora,
OH) as the second antibody. Protein standard serum
Nor-Partigen (Behringwerke AG, Marburg, Germany)
was used as the standard. The sputum samples were
mixed with 9 volumes of saline, and homogenized
using a Polytron homogenizer in an ice-bath for1min.
The test samples were finally diluted 1,000- to10,000-fold
with 10-fold diluted Block Ace (Snow Brand Milk
Products, Tokyo).
Statistical analysis :
The protease activities and protein concentrations
in the sputum samples from each patient group were
expressed as the mean±SD. The significance of
differences between values for each group was
tested by the Mann-Whitney U-test.
RESULTS
Fibrinogen concentration in sputum samples from
patients with chronic airway diseases
Figure 1 shows the fibrinogen concentration in
mucoid sputum samples from CB and BA patients,
and in purulent sputum samples from BE patients.
The concentration of fibrinogen was significantly
higher in mucoid sputum samples from BA patients
Fig.1. Concentration of fibrinogen in sputum samples from patients
with chronic bronchitis, bronchial asthma and bronchiectasis
Horizontal lines show mean values. Abbreviations M : mucoid ;
P : purulent ; CB : chronic bronchitis ; BA : bronchial asthma ; BE :
bronchiectasis p<0.001:Mann-Whitney U-test for difference from
the mucoid sputum from CB patients
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(6.3±5.5) than in those from CB patients (1.9±
1.1), and was significantly higher in the purulent
sputum samples from BE patients (18.8±8.8) than
in the mucoid sputa from both CB and BA patients.
Table 1 shows trypsin-like activity, elastase-like
activity and albumin concentration in sputa, from
patients with different diseases affecting the airway.
Elastase activity was measured to estimate the
extent of sputum purulence because neutrophil
polymorphonuclear leukocytes contain much elastase,
and actively release it extracellularly (14). As shown in
this Table, elastase activity was about 1000-3000-fold
higher in the purulent sputum samples from BE
patients than in the mucoid sputum samples from
both CB and BA patients. This result indicated that
our judgment of purulence of sputum based on macro-
scopic appearance was roughly correct. The elastase
activity in the mucoid sputum samples from CB
patients was not compared with that in those from
BA patients, because its activity was very low in both
groups.
Trypsin-like activity was slightly higher in the
mucoid sputum samples from BA patients than in
those from CB patients. This activity was signifi-
cantly lower in purulent sputum samples from BE
patients, as compared with both types of mucoid sputum
samples.
Albumin concentration was significantly (about
3-fold) higher in the purulent sputum samples from
BE patients than in mucoid sputum samples from
patients with CB or BA, and it had a tendency to be
slightly higher in the mucoid sputum samples from
patients with BA than in those from CB patients.
Gel filtration of extracts of mucoid sputum samples
from patients with chronic bronchitis (CB)
Figure 2 shows the elution patterns of purified
HAT and mast cell tryptase in gel filtration through
Sephadex G-200. The peak concentrations of HAT
(molecular weight, 27 kDa) (1) and that of lung mast
cell tryptase (molecular weight, about 130 kDA) (6)
were located in tube 50 and tube 34, respectively.
As shown in Fig.3, in gel filtration of mucoid
sputum extracts from 2 patients with CB, prominant
peak of trypsin-like activity was detectable only at
tube 50. Thus trypsin-like activity was detectable at
a fraction corresponding to HAT, and not at a frac-
tion corresponding to mast cell tryptase. The elution
patterns of mucoid sputum extracts from other
patients with CB were similar to those shown in
Fig.2.
Analysis of HAT fibrinogenolytic activity by SDS-PAGE
1) Effect of HAT on 2,000/ fibrinogen
Figure 4 shows the time courses (between 15 min
and 16 hrs) of HAT fibrinogenolytic activity at a
concentration of 10mU/, at pH8.6. Lane8 shows
electrophoretic mobility of control fibrinogen incu-
bated in buffer alone for 4 hrs. In this lane, there
were three major bands, whose molecular weights
were 68,000, 58,000 and 48,000, respectively. This
result was roughly in accordance with the reports
of previous investigators who showed that fibrino-
gen consisted of two of three subunits, α-chain
(MW68,000), β-chain (MW54,000) and γ-chain
(MW 48,000) (15). Mills and Karpatkin (16) reported
that SDS-PAGE of reduced fibrinogen revealed two
α-chain species which differed in molecular weight
by 3000, because the α-chain band consisted of two
bands, a major and a minor one. In lane 8 of Fig.4,
Table 1. Trypsin-like activity, elastase-like activity and albumin concentration in sputum samples of patients with chronic bronchitis,
bronchial asthma and bronchiectasis
Chronic bronchitis
mucoid
(n=22)
Bronchial asthma
mucoid
(n=26)
p※ Bronchiectasis
purulent
(n=27)
p※
Trypsin-like
activity
milliunit/ml 23.46±18.03 46.90±43.96 p<0.05 14.92±8.23 p<0.001
Elastase-like
activity
microunit/ml 15±18 6±14 16,975±8,545 p<0.001
Albumin μg/ml 331±201 457±289 ns 1,206±679 p<0.001
Values are means±SD.
※Mann-Whitney U-test for difference from mucoid sputum samples of patients with chronic bronchitis.
ns : not significant
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the α-chain band was wide but stained less intense
compared with the β-and γ-chain bands. This is
thought to be due to the fact that the chain consists
of two species.
In the HAT-treated fibrinogen, the α-chain was
completely lost within 15 min. On the other hand,
cleavage of the β-chain was not detectable up to 180
min, but the band almost completely disappeared
after 16 hrs of incubation. The cleavage of γ-chain
was not clear at any determination point.
When fibrinogen was incubated with HAT at pH
7.4, it was cleaved by HAT in almost the same manner
as at pH 8.6 (data not shown).
Figure 5 shows the effect of HAT concentration
on the cleavage of fibrinogen. The reaction mixtures
containing HAT at concentrations varying from 0.6
to 10.0 mU/, and 50 mU Tris-HCl (pH 8.6 or pH
7.4), were incubated at 37℃ for 4hrs. As clear-
ly shown in Fig.5, HAT cleaved fibrinogen in a
dose-dependent manner. The cleavage of α-chain
Fig.2. Gel filtration of purified HAT and lung mast cell tryptase
About 80 mU of purified HAT or mast cell tryptase dissolved in
0.05M Tris-HCl buffer-0.15M NaCl was applied to a column
(2.2×65 cm) of Sephadex G-200 equilibrated with the same buffer.
Elution was carried out at a flow rate of 15/hr at 4℃, and the
eluate was collected in fractions of 4. HAT activity was measured
with Boc-Phe-Ser-Arg-MCA, and mast cell tryptase activity with
Boc-Gln-Ala-Arg-MCA, as the substrate.
Fig.3. Gel filtration of extract of mucoid sputum from patients
with chronic bronchitis on Sephadex G-２００
Two of mucoid sputum extract prepared as described inMaterials
and Methods, was subjected to gel filtration through Sephadex
G-200 in the same way as described for Fig.2.
●───●measured with Boc-Phe-Ser-Arg-MCA as the substrate
◯………◯measured with Boc-Gln-Ala-Arg-MCA as the substrate
Fig.4. Fibrinogenolytic activity of HAT against human fibrinogen
― Time course ―
Fibrinogen at a concentration of 2,000/ was mixed with HAT
at a concentration of 10 mU/, and 50 mU Tris-HCl (pH 8.6)
in a total volume of 0.5, and then incubated at 37℃ for 15
min-16 hrs. The reaction was stopped by placing the mixture in
an ice-bath. Ten μ of each of the reaction mixture was subjected
to SDS-PAGE on a gradient gel (Multigel 10/20, Daiichi Pure
Chemicals) under a denaturing and reducing condition by the
method of Laemmli (11).The gel was calibrated with high range
standards (Promega). The proteins trapped in the gel were
stained with coomassie brilliant blue.
Incubation time : lane1, 15min ; lane2, 30min ; lane3, 60min ; lane4,
120 min ; lane 5, 180 min ; lane 6, 240 min ; lane 7, 16 hrs ; lane
8, control incubated without HAT for 240 min
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was the most marked, that of β-chain was relatively
clear, while that of γ-chain was not detectable. This
figure also showed that the pattern of cleavage of
fibrinogen by HAT incubated at pH7.4 was very
similar to that at pH 8.6. This was more clear when
fibrinogen was incubated with 5-10 mU/ HAT.
The results of Figs 4 and 5 showed that HAT
degradates first the α-chain of fibrinogen, and
more slowly β-chain.
2) Effect of HAT on 4-16/ fibrinogen
Fibrinogen in relatively low concentrations was
incubated with 10 mU/ HAT at pH 8.6 for 4 hrs.
As shown in Fig.6, the α-chain completely disappeared
at each fibrinogen concentration of 4, 8 and 16/
, but cleavage of β-chain was not so prominent at
any concentration of fibrinogen, compared with the
respective control incubated without HAT. The
cleavage of the γ-chain was almost not detectable
when fibrinogen was used at concentrations of 4
and8/. The α-chain was completely cleaved
by HAT at pH 7.4 and at pH 8.6.
Analysis of the optimum pH for HAT-induced cleavage
of fibrinogen using a kit for measuring FPA
Thrombin cleaves the bond between arginine
and glycine (arginyl-glycine bond) to release FPA
(16 amino acids) from the NH2-terminal segment
of the fibrinogen α-chain(17). Previously, we showed
that HAT also split the COOH-terminal side of
arginine in various kinds of model peptides like trypsin
(18). The experiments of Figs.4, 5 and 6 showed
that HAT can cleave human fibrinogen, especially
the α-chain of fibrinogen. From these results, we
thought that HAT may cleave the arginyl-glycine
bond in the α-chain of fibrinogen like thrombin, and
FPA or FPA reactive peptides may be released from
fibrinogen incubated at 37℃with HAT. And we
showed that when human fibrinogen was incu-
bated with HAT under the same conditions described
in the previous section, the amount of substances
Fig.7. Effect of pH on the fibrinogenolytic activity of HAT
Reaction mixtures containing 2,000/ fibrinogen, 5 mU/
HAT and 50 mU Tris-HCl (pH 7.6-9.4) or Hepes (pH 6.8-7.6) in
a total volume of 0.25, were incubated at 37℃ for 240 min.
Then fibrinopeptideA (FPA) in the mixtures was measured by
an EIA kit for FPA (Asserachrom).
Fig.5. Fibrinogenolytic activity of HAT against human fibrinogen
- - - Effect of the concentration of HAT - - -
Experimental procedures, unless otherwise stated, were carried
out in the same way as described for Fig.4. The reaction mixtures
containing HAT at concentrations varying from 0.625 to 10.0
mU/, and 50mU Tris-HCl (pH8.6 or pH7.4), were incubated
at 37℃ for 240 min. Lanes 1-5 correspond to reaction mixtures
incubated at pH 8.6, and lanes 6-9 to those incubated at pH 7.4
Concentration of HAT (mU/) : lane 1, 10.0 ; lane 2, 5.0 ; lane
3, 2.5 ; lane4, 1.25 ; lane5, 0.625 ; lane6, 10.0 ; lane7, 5.0 ; lane8,
2.5 ; lane 9, 1.25
Fig.6. Fibrinogenolytic activity of HAT against a low concentration
of human fibrinogen
Reaction mixtures containing fibrinogen at concentrations of 4,
8 or 16/, and 5 mU/ HAT and 50 mU Tris-HCl (pH 8.6)
in a total volume of 5, were incubated at 37℃ for 240 min,
cooled in an ice-bath, concentrated using a vaporized centrifuge,
and dissolved in0.25, 0.50 and 2.0, respectively, of 50mU Tris-HCl
(pH 6.8). Ten μof the mixtures was subjected to SDS-PAGE
as described for Fig.4. The proteins trapped in the gel were
silver-stained.
Concentration of fibrinogen :
lane 1, 4/ without HAT ; lane 2, 4/ with HAT ; lane 3,
8/ without HAT ; line 4,8/ with HAT ; lane 5,16/
without HAT ; lane 6, 16/ with HAT
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measured by the assay kit for FPA increased in
proportion to the incubation time and HAT con-
centration. Therefore the effect of pH on the
fibrinogenolytic activity of HAT was examined using
this kit for FPA. As shown in Fig.7, the fibrinogenolytic
activity of HAT was maximal at pH 8.5-8.6.
Thrombin-induced clotting capacity of HAT-treated
fibrinogen
After the reaction mixtures containing 2,000/
 fibrino-gen, 10 mU/ HAT and 50 mU Tris-HCl
(pH 7.4), were incubated at 37℃ for 10-80 min, the
thrombin-induced clotting time of HAT-treated
fibrinogen was measured. In the present assay system,
the clotting time of intact fibrinogen was 20±5 sec
(n=5). As shown in Fig.8, HAT prolonged the clotting
time of treated fibrinogen in a time-dependent
manner, from the initial value of 20 sec to about 60
sec after 40 min of incubation with HAT. We thought
that the fibrinogen which did not clot at 120 sec
after it had been incubated with thrombin, had almost
completely lost its capacity to clot, because it finally
did not clot after a longer time. Thus Fig.8 shows
that fibrinogen treated with HAT for over 60 min
almost completely lost its capacity to clot.
Fibrinogen was treated with HAT at various
concentra-tions (0.36-6mU/) at 37℃ for 4hrs.
As shown in Fig.9, HAT prolonged the clotting time
of fibrinogen in a dose-dependent manner from the
initial value (20sec) to 45sec at concentrations from
0 to 3mU/, and the fibrinogen treated with 6
mU/ HAT almost completely lost its capacity to
clot.
DISCUSSION
Previous reports on serine proteases of human
airways have indicated that at least two kinds of
trypsin-like proteases, mast cell tryptase (19-20) and
HAT (1-2), are secreted or released into the human
airway lumen from specific inflammatory cells or
secretory cells localized in the airway walls. Mast
cells are thought to release tryptase mainly into the
airway walls, because in the airway, they are mainly
localized in the submucosal layer (20), and they
actively release tryptase which is already activated
and translocated into secretory granules at their
degranulation (20). On the other hand, HAT is
thought to be released or secreted into the airway
lumen, because much of it is contained in the airway
mucus, such as sputum. Besides, we have postulated
based on the analysis of the cloned cDNA for HAT
that HAT is released or secreted from airway walls
after its precursor (MW47kDa) is subjected to
limited proteolysis and changed into its active and
mature form, HAT (2). Gel filtration of extracts of
mucoid sputum samples supported this idea, because
the trypsin-like activity of these sputum samples was
mainly due to HAT.
The elastase activities of purulent sputa from BE
patients were much higher than those of mucoid sputa
Fig.8. Effect of HAT treatment on thrombin-induced clotting
time of the fibrinogen
―Effect of pretreatment time ―
Reaction mixtures containing 2,000/ fibrinogen, 10 mU/
HAT and 50 mU Tris-HCl (pH 7.4), were incubated at 37℃ for
10-80min, and then cooled in an ice-bath. The reaction mixtures
and a solution containing 2.5 unit/ thrombin in 50 mU Tris-
HCl buffer (pH 7.4) were kept at room temperature separately.
Then the thrombin-induced clotting time of HAT-treated fibrinogen
was measured by incubating a mixture of 100 μeach of the
HAT-treated fibrinogen solution and thrombin solution in a plastic
tube at 37℃.
Fig.9. Effect of the concentration of HAT on the thrombin-induced
clotting time of HAT-treated fibrinogen
2,000/ fibrinogen was preincubated with various concentrations
of HAT (0.3-6 mU/) at 37℃ for 240 min. The thrombin-induced
clotting time of HAT-treated fibrinogen was measured as de-
scribed for Fig.8.
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from CB and BA patients. This result was in good
accordance with the report of Stockley et al . (14) that
purulent sputa from BE patients contained much
neutrophil elastase. On the other hand, the trypsin-like
activity was significantly lower in the purulent sputa
from BE patients than in the mucoid sputa from
CB and BA patients. The lower level of trypsin-like
activity in BE patients is thought to be partly due to
the fact that HAT released into airway lumen is
hydrolyzed by proteases such as neutrophil elastase,
because neutrophi elastase can hydrolyze various
kinds of endogenous proteins (21).
Considering localization of HAT, we think that
HAT plays some physiological role mainly in the
airway lumen, on the airway mucous membranes, by
causing limited cleavage of some endogenous proteins
(peptides) or inhaled proteins (peptides).
Schwartz et al. (22) have reported that human lung
mast cell tryptase cleaves fibrinogen. In a previous
report (1), we showed that HAT also cleaved fibrinogen.
Extravascular fibrin deposition accompanies tissue
inflammation and serves as a provisional matrix for
subsequent repair, and the fibrin gel participates in
progression of tissue injury by modulating cell
accumulation, activation and migration, angiogenesis,
synthesis of granulation tissue, and collagen deposition
(23). Moreover, fibrin gel on themucousmembranes
of airways, is thought to disturb mucociliary movement,
the most fundamental defense system of the airways,
because of its rheological property. We thought that
probably HAT may serve as an anticoagulant by
cleaving the fibrinogen transported to the mucous
membranes via the blood stream, because the capacity
of HAT-degradated fibrinogen to clot in the presence
of thrombin might decrease or be completely lost.
This study was undertaken to test in vitro the possibility
of HAT being related to the prevention of fibrin deposition
on the mucous membranes of airways due to its
fibrinogenolytic action.
It is known that the concentration of fibrinogen in
blood of healthy subjects is in the range of 2,000-4,000
/ or 6-12×10-6 M (24). To roughly estimate the
concentration of fibrinogen in the bronchial secretion
(respiratory tract fluid) of patients with chronic
airway diseases, we measured the concentration of
fibrinogen in their sputum samples by ELISA.
Regarding mucoid sputa, the concentration of fibrino-
gen was higher in those from BA patients than in
those from CB patients, and it was higher in purulent
sputa from BE patients than in the mucoid sputa
from CB patients. The concentration of fibrinogen
in the sputum samples was about 1/100-1/1,000 of
that found in blood. We think that the concentration
of fibrinogen in sputum sample may roughly reflect
that on the mucous membrane of the airway. All
the fibrinogen in the sputum or bronchial secretion
derives from the blood stream. The higher concentration
of fibrinogen found in the purulent sputum samples
was thought to be due to increased transudation
accompanied by infection, in the airways. The higher
concentration of fibrinogen found in the mucoid
sputum samples from BA patients compared with
those from CB patients was also probably due to a
more marked transudation in the airway in BA than in
CB. Kawata et al. (25) reported using immunohistochemical
techniques that fibrinogen is present in all mucoid
sputum samples from patients with CB and BA, which
they had examined, while fibrin was detectable only
in a part of them.
As shown in Table 1, the concentration of HAT
(trypsin-like enzyme) in the sputum samples was about
10-40mU/. Therefore, we examined the fibrinogenolytic
activity of HAT using HAT at a concentration of 5-10
mU/. Our SDS-PAGE study clarified that when
fibrinogen was incubated with HAT, the α-chain was
preferentially cleaved, the β-chain was cleaved to a
lesser degree, and the γ-chain was almost not cleaved
by HAT, and that HAT can cleave fibrinogen not only
when present at a concentration similar to that found
in blood, but also when present at the concentration
it is found in sputum samples. The Km value of the
reaction between HAT and human fibrinogen is
unknown, mainly because we did not analyze in detail
the degradation products of HAT-treated fibrinogen.
But the result of SDS-PAGE (Fig.6) strongly suggested
that HAT can cleave fibrinogen at concentrations
similar to that it is found in bronchial secretion.
When thrombin attacks fibrinogen, it removes the
NH2-terminal fibrinopeptide moieties (fibrinopeptide A
and fibrinopeptide B), amounting only to about 3%
of the total weight of fibrinogen (15). Thus the
resulting fibrin monomers represent 97% of the
fibrinogen molecule. Therefore the SDS-PAGE study
also showed that the degradation of fibrinogen
induced by HAT is clearly different, because both
the α-chain and the β-chain were completely lost after
HAT treatment.
When fibrinogen was incubated with HAT in vitro,
the production of FPA increased in proportion to
the concentration of HAT and treatment time. As
described above, we do not think this was due to the
fact that HAT cleaves only the arginyl-glycine bond,
which is attacked specifically by thrombin, in the
α-chain of fibrinogen. However, the amount of FPA
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reactive substances was thought to be proportional
to the amount of fibrinogen cleaved by HAT. On
the basis of this idea, the optimum pH for the
fibrinogenolytic activity of HAT was examined using
this kit, and was shown to be pH8.5-8.6 in vitro.
However, HAT also cleaved fibrinogen at pH 7.4 in
vitro.
The clotting activity of HAT-treated fibrinogen
induced by thrombin decreased or completely disappeared
in vitro. This result suggests that HAT may act as
an anticoagulant in the airways, especially on the
mucous membranes, if it cleaves fibrinogen before
thrombin reacts with the latter.
It is postulated that two kinds of antibodies against
human fibrinogen, which we used for the ELISA of
fibrinogen, react with multiple antigenic sites of
human fibrinogen and thus with considerable parts
of fragments produced from human fibrinogen by
HAT action, because they are polyclonal antibodies.
When the concentration of human fibrinogen, which
was treated at 37℃ by HAT at 10 mU/ for 1 to 4
hr in vitro, was measutred by the ELISA, it was not
decreased compared with non-treated control (our
unpublished data). Therefore even if the fibrinogen
contained in the sputum samples is already partially
cleaved by HAT, probably we can measure roughly
the fibrinogen concentration of the sputum samples
by the present ELISA.
Further studies seem to be necessary to clarify
whether HAT can cleave fibrinogen in vivo (in the
airway lumens) as it cleaves the latter in vitro, and
whether HAT participates in the anticoaglulation
process in the airways.
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